老年人抗血小板、抗凝溶栓治疗的疗效和安全性  

Efficacy and safety of anti-platelet,anticoagulant and fibrinolytic therapy in elderly

作　　者：黄震华[1] 

机构地区：[1]上海交通大学医学院附属第九人民医院心血管病研究室,上海200011

出　　处：《中国新药与临床杂志》2014年第1期22-26,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：老年人易发生血栓栓塞性疾病。老年人体内水分减少,脂肪增多,肝、肾功能减退。合并用药多,易发生药物一药物相互作用。老年人血小板反应性高、凝血因子活性高、纤维蛋白溶酶活性低。本文对各种抗血小板、抗凝、溶栓治疗的疗效和安全性进行了讨论,并期望对老年人更有效、更安全的药物问世。The elderly are apt to suffer from thromboembolism, because they are associated with decreased total body water, increased total body fat, decreased hepatic and renal function, increased polypharmacy, and are apt to suffer from drug-drug interactions. The elderly are associated with increased platelet reactivity, increased coagulation factor activity, and decreased fibrinolytic activity. The efficacy and safety of antiplatelet, anticoagulant and fibrinolytic therapy in the elderly were discussed in this paper. More effective and safe drugs were awaited for the elderly.

关 键 词：老年人 血小板 血液凝固 溶栓 安全 

分 类 号：R973.2[医药卫生—药品]